The Principles, Enzymes, and Pathways of Human Steroidogenesis

Endocrinology: Adult and Pediatric, Sixth Edition

Volumn 2, Issue , 2010, Pages 1784-1804

  Auchus, Richard J ^a   Miller, Walter L ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951642537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5583-9.00096-4     Document Type: Chapter

References (245)

1. PF Hall (1986) Cytochromes P450 and the regulation of steroid synthesis. Steroids 48 133-196.
2. AK Agarwal and RJ Auchus (2005) Minireview: cellular redox state regulates hydroxysteroid dehydrogenase activity and intracellular hormone potency. Endocrinology 146 2531-2538.
3. WL Miller (2005) Regulation of steroidogenesis by electron transfer. Endocrinology 146 2544-2550.
4. TM Penning (1997) Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 18 281-305.
5. DP Sherbet, M Papari-Zareei, N Khan, et al. (2007) Cofactors, redox state, and directional preferences of hydroxysteroid dehydrogenases. Mol Cell Endocrinol 265–266 83-88.
6. M Papari-Zareei, A Brandmaier and RJ Auchus (2006) Arginine 276 controls the directional preference of AKR1C9 (rat liver 3α-hydroxysteroid dehydrogenase) in human embryonic kidney 293 cells. Endocrinology 147 100-107.
7. R Voutilainen and WL Miller (1987) Coordinate tropic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain cleavage enzyme, P450scc, in human steroidogenic tissues. Proc Natl Acad Sci USA 84 1590-1594.
8. S Mesiano, SH Mellon and RB Jaffe (1993) Mitogenic action, regulation, and localization of insulin-like growth factors in the human fetal adrenal gland. J Clin Endocrinol Metab 76 968-976.
9. S Mesiano, SH Mellon, D Gospodarowicz, et al. (1991) Basic fibroblast growth factor expression is regulated by corticotropin in the human fetal adrenal: a model for adrenal growth regulation. Proc Natl Acad Sci USA 88 5428-5432.
10. CL Coulter, LC Read, BR Carr, et al. (1996) A role for epidermal growth factor in the morphological and functional maturation of the adrenal gland in the fetal rhesus monkey in vivo. J Clin Endocrinol Metab 81 1254-1260.
11. DM Stocco and BJ Clark (1996) Regulation of the acute production of steroids in steroidogenic cells. Endocr Rev 17 221-244.
12. BJ Clark, J Wells, SR King, et al. (1994) The purification, cloning and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (StAR). J Biol Chem 269 28314-28322.
13. D Lin, T Sugawara, JF Strauss III, et al. (1995) Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science 267 1828-1831.
14. HS Bose, T Sugawara, JF Strauss III, et al. (1996) The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 335 1870-1878.
15. K Caron, S-C Soo, W Wetsel, et al. (1997) Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 94 11540-11545.
16. WL Miller (2007) StAR search: What we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import. Mol Endocrinol 21 589-601.
17. F Arakane, T Sugawara, H Nishino, et al. (1996) Steroidogenic acute regulatory protein (StAR) retains activity in the absence of its mitochondrial targeting sequence: implications for the mechanism of StAR action. Proc Natl Acad Sci USA 93 13731-13736.
18. H Bose, VR Lingappa and WL Miller (2002) Rapid regulation of steroidogenesis by mitochondrial protein import. Nature 417 87-91.
19. Y Tsujishita and JH Hurley (2000) Structure and lipid transport mechanism of a StAR-related domain. Nat Struct Biol 7 408-414.
20. HS Bose, RM Whittal, MA Baldwin, et al. (1999) The active form of the steroidogenic acute regulatory protein, StAR, appears to be a molten globule. Proc Natl Acad Sci U S A 96 7250-7255.
21. BY Baker, DC Yaworsky and WL Miller (2005) A pH-dependent molten globule transition is required for activity of the steroidogenic acute regulatory protein, StAR. J Biol Chem 280 41753-41760.
22. RC Tuckey, MJ Headlam, HS Bose, et al. (2002) Transfer of cholesterol between phospholipid vesicles mediated by the steroidogenic acute regulatory protein (StAR). J Biol Chem 277 47123-47128.
23. BY Baker, RF Epand, RM Epand, et al. (2007) Cholesterol binding does not predict activity of the steroidogenic acute regulatory protein, StAR. J Biol Chem 282 10223-10232.
24. T Hauet, ZX Yao, HS Bose, et al. (2005) Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into Leydig cell mitochondria. Mol Endocrinol 19 540-554.
25. M Bose, RM Whittal, WL Miller, et al. (2008) Steroidogenic activity of StAR requires contact with mitochondrial VDAC1 and phosphate carrier protein. J Biol Chem 283 8837-8845.
26. IP Artemenko, D Zhao, DB Hales, et al. (2001) Mitochondrial processing of newly synthesized steroidogenic acute regulatory protein (StAR), but not total StAR, mediates cholesterol transfer to cytochrome P450 side chain cleavage enzyme in adrenal cells. J Biol Chem 276 46583-46596.
27. WL Miller and JF Strauss III (1999) Molecular pathology and mechanism of action of the steroidogenic acute regulatory protein, StAR. J Steroid Biochem Mol Biol 69 131-141.
28. R Voutilainen, J Tapanainen, B Chung, et al. (1986) Hormonal regulation of P450scc (20,22-desmolase) and P450c17 (17α-hydroxylase/17,20-lyase) in cultured human granulosa cells. J Clin Endocrinol Metab 63 202-207.
29. C Tsigos, K Arai, W Hung, et al. (1993) Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 92 2458-2461.
30. JWM Martens, M Verhoef-Post, N Abelin, et al. (1998) A homozygous mutation in the luteinizing hormone receptor causes partial Leydig cell hypoplasia: correlation between receptor activity and phenotype. Mol Endocrinol 12 775-784.
31. A Shenker (1995) G protein-coupled receptor structure and function: the impact of disease-causing mutations. Baillieres Clin Endocrinol Metab 9 427-451.
32. KL Parker and BP Schimmer (1997) Steroidogenic factor 1:A key determinant of endocrine development and function. Endocr Rev 18 361-377.
33. P Zhang, H Rodriguez and SH Mellon (1995) Transcriptional regulation of P450scc gene expression in neural and in steroidogenic cells: implications for regulation of neurosteroidogenesis. Mol Endocrinol 9 1571-1582.
34. N Huang and WL Miller (2000) Cloning of factors related to HIV-inducible LBP proteins that regulate steroidogenic factor-1-independent human placental transcription of the cholesterol side-chain cleavage enzyme, P450scc. J Biol Chem 275 2852-2858.
35. YC Henderson, MJ Frederick, MT Wang, et al. (2008) LBP-1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation. DNA Cell Biol 27 71-79.
36. X Luo, Y Ikeda and KL Parker (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77 481-490.
37. MW Nachtigal, Y Hirokawa, DL Enyeart-VanHouten, et al. (1998) Wilms’ tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. Cell 93 445-454.
38. GD Hammer, I Krylova, Y Zhang, et al. (1999) Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell 3 521-526.
39. ER Simpson, Y Zhao, VR Agarwal, et al. (1997) Aromatase expression in health and disease. Recent Prog Horm Res 52 185-214.
40. Y Labrie, F Durocher, Y Lachance, et al. (1995) The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol 14 849-861.
41. RC Tuckey and KJ Cameron (1993) Catalytic properties of cytochrome P-450scc purified from the human placenta: comparison to bovine cytochrome P-450scc. Arch Biochem Biophys 1163 185-194.
42. O Guryev, RA Carvalho, S Usanov, et al. (2003) A pathway for the metabolism of vitamin D3:unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc Natl Acad Sci U S A 100 14754-14759.
43. K Morohashi, K Sogawa, T Omura, et al. (1987) Gene structure of human cytochrome P-450(scc), cholesterol desmolase. J Biochem 101 879-887.
44. B Chung, KJ Matteson, R Voutilainen, et al. (1986) Human cholesterol side-chain cleavage enzyme, P450scc: cDNA cloning, assignment of the gene to chromosome 15, and expression in the placenta. Proc Natl Acad Sci USA 83 8962-8966.
45. SM Black, JA Harikrishna, GD Szklarz, et al. (1994) The mitochondrial environment is required for activity of the cholesterol side-chain cleavage enzyme, cytochrome P450scc. Proc Natl Acad Sci USA 91 7247-7251.
46. ME John, MC John, V Boggaram, et al. (1986) Transcriptional regulation of steroid hydroxylase genes by corticotropin. Proc Natl Acad Sci USA 83 4715-4719.
47. SH Mellon and C Vaisse (1989) cAMP regulates P450scc gene expression by a cycloheximide-insensitive mechanism in cultured mouse Leydig MA-10 cells. Proc Natl Acad Sci USA 86 7775-7779.
48. PQ Barrett, WB Bollag, CM Isales, et al. (1989) The role of calcium in angiotensin II-mediated aldosterone secretion. Endocr Rev 10 496-518.
49. CCD Moore, ST Brentano and WL Miller (1990) Human P450scc gene transcription is induced by cyclic AMP and repressed by 12-O-tetradecanolyphorbol-13-acetate and A23187 by independent cis-elements. Mol Cell Biol 10 6013-6023.
50. CCD Moore, DW Hum and WL Miller (1992) Identification of positive and negative placental-specific basal elements, a transcriptional repressor, and a cAMP response element in the human gene for P450scc. Mol Endocrinol 6 2045-2058.
51. N Huang and WL Miller (2005) LBP proteins modulate SF1-independent expression of P450scc in human placental JEG-3 cells. Mol Endocrinol 19 409-420.
52. EE Baulieu (1997) Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 52 1-32.
53. X Yang, K Iwamoto, M Wang, et al. (1993) Inherited congenital adrenal hyperplasia in the rabbit is caused by a deletion in the gene encoding cytochrome P450 cholesterol side-chain cleavage enzyme. Endocrinology 132 1977-1982.
54. MC Hu, NC Hsu, NB El Hadj, et al. (2002) Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1. Mol Endocrinol 16 1943-1950.
55. T Tajima, K Fujieda, N Kouda, et al. (2001) Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Metab 86 3820-3825.
56. CJ Kim, L Lin, N Huang, et al. (2008) Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab 93 696-702.
57. D Apter, A Pakarinen, GL Hammond, et al. (1979) Adrenocortical function in puberty. Acta Paediatr Scand 68 599-604.
58. N Orentreich, JL Brind, RL Rizer, et al. (1984) Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59 551-555.
59. S Nakajin, JE Shively, P Yuan, et al. (1981) Microsomal cytochrome P450 from neonatal pig testis: two enzymatic activities (17α-hydroxylase and C17,20-lyase) associated with one protein. Biochemistry 20 4037-4042.
60. MX Zuber, ER Simpson and MR Waterman (1986) Expression of bovine 17α-hydroxylase cytochrome P450 cDNA in non-steroidogenic (COS-1) cells. Science 234 1258-1261.
61. J Picado-Leonard and WL Miller (1987) Cloning and sequence of the human gene encoding P450c17 (steroid 17α-hydroxylase/17,20 lyase): Similarity to the gene for P450c21. DNA 6 439-448.
62. BC Chung, J Picado-Leonard, M Haniu, et al. (1987) Cytochrome P450c17 (steroid 17α-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc Natl Acad Sci U S A 84 407-411.
63. P Lee-Robichaud, JN Wright, ME Akhtar, et al. (1995) Modulation of the activity of human 17α-hydroxylase-17,20-lyase (CYP17) by cytochrome b 5:endocrinological and mechanistic implications. Biochem J 308 901-908.
64. RJ Auchus, TC Lee and WL Miller (1998) Cytochrome b 5 augments the 17,20 lyase activity of human P450c17 without direct electron transfer. J Biol Chem 273 3158-3165.
65. M Katagiri, N Kagawa and MR Waterman (1995) The role of cytochrome b 5 in the biosynthesis of androgens by human P450c17. Arch Biochem Biophys 317 343-347.
66. D Lin, SM Black, Y Nagahama, et al. (1993) Steroid 17α-hydroxylase and 17,20 lyase activities of P450c17: contributions of serine106 and P450 reductase. Endocrinology 132 2498-2506.
67. CE Flück, WL Miller and RJ Auchus (2003) The 17,20-lyase activity of cytochrome P450c17 from human fetal testis favors the Δ5 steroidogenic pathway. J Clin Endocrinol Metab 88 3762-3766.
68. TC Lee, WL Miller and RJ Auchus (1999) Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab 84 2104-2110.
69. RJ Auchus, AS Kumar, CA Boswell, et al. (2003) The enantiomer of progesterone (ent-progesterone) is a competitive inhibitor of human cytochromes P450c17 and P450c21. Arch Biochem Biophys 409 134-144.
70. W Arlt, RJ Auchus and WL Miller (2001) Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. J Biol Chem 276 16767-16771.
71. MK Gupta, OL Guryev and RJ Auchus (2003) 5α-reduced C21 steroids are substrates for human cytochrome P450c17. Arch Biochem Biophys 418 151-160.
72. JD Wilson, RJ Auchus, MW Leihy, et al. (2003) 5α-androstane-3α,17β-diol is formed in tammar wallaby pouch young testes by a pathway involving 5α-pregnane-3α,17α-diol-20-one as a key intermediate. Endocrinology 144 575-580.
73. RJ Auchus (2004) The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 15 432-438.
74. L Milewich, BB Mendonca, I Arnhold, et al. (1995) Women with steroid 5α-reductase 2 deficiency have normal concentrations of plasma 5α-dihydroprogesterone during the luteal phase. J Clin Endocrinol Metab 80 3136-3139.
75. AM Moisan, ML Ricketts, V Tardy, et al. (1999) New insight into the molecular basis of 3β-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene in eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 84 4410-4425.
76. NA Hanley and W Arlt (2006) The human fetal adrenal cortex and the window of sexual differentiation. Trends Endocrinol Metab 17 391-397.
77. PR Ortiz de Montellano (1995) Oxygen activation and reactivity. PR Ortiz de Montellano,(Ed.) Cytochrome P-450:Structure, Mechanism, and Biochemistry ed 2 New York: Plenum 245-303.
78. RJ Auchus and WL Miller (1999) Molecular modeling of human P450c17 (17α-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. Mol Endocrinol 13 1169-1182.
79. GB Cutler, M Glenn, M Bush, et al. (1978) Adrenarche: a survey of rodents, domestic animals and primates. Endocrinology 103 2112-2118.
80. W Arlt, JW Martens, M Song, et al. (2002) Molecular evolution of adrenarche: structural and functional analysis of P450c17 from four primate species. Endocrinology 143 4665-4672.
81. L Zhang, H Rodriguez, S Ohno, et al. (1995) Serine phosphorylation of human P450c17 increases 17,20 lyase activity: implications for adrenarche and for the polycystic ovary syndrome. Proc Natl Acad Sci USA 92 10619-10623.
82. AV Pandey and WL Miller (2005) Regulation of 17,20 lyase activity by cytochrome b 5 and by serine phosphorylation of P450c17. J Biol Chem 280 13265-13271.
83. AA Bremer and WL Miller (2008) The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril 89 1039-1048.
84. AV Pandey, SH Mellon and WL Miller (2003) Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17. J Biol Chem 278 2837-2844.
85. AD Nguyen, SM Mapes, CJ Corbin, et al. (2008) Morphological adrenarche in rhesus macaques: development of the zona reticularis is concurrent with fetal zone regression in the early neonatal period. J Endocrinol 199 367-378.
86. T Suzuki, H Sasano, J Takeyama, et al. (2000) Developmental changes in steroidogenic enzymes in human postnatal adrenal cortex: immunohistochemical studies. Clin Endocrinol (Oxf) 53 739-747.
87. N Huang and WL Miller (2005) Regulation of cytochrome b 5 gene transcription by Sp3, GATA-6, and steroidogenic factor 1 in human adrenal NCI-H295A cells. Mol Endocrinol 19 2020-2034.
88. JS Gell, BR Carr, H Sasano, et al. (1998) Adrenarche results from development of a 3β-hydroxysteroid dehydrogenase-deficient adrenal reticularis. J Clin Endocrinol Metab 83 3695-3701.
89. EG Biglieri, MA Herron and N Brust (1966) 17-hydroxylation deficiency in man. J Clin Invest 45 1946-1954.
90. RJ Auchus (2001) The genetics, pathophysiology, and management of human deficiencies of P450c17. Endocrinol Metab Clin North Am 30 101-119.
91. M Costa-Santos, CE Kater and RJ Auchus (2004) Two prevalent CYP17 mutations and genotype/phenotype correlations in 24 Brazilian patients with 17-hydroxylase deficiency. J Clin Endocrinol Metab 89 49-60.
92. MK Gupta, DH Geller and RJ Auchus (2001) Pitfalls in characterizing P450c17 mutations associated with isolated 17,20-lyase deficiency. J Clin Endocrinol Metab 86 4416-4423.
93. DH Geller, RJ Auchus, BB Mendonça, et al. (1997) The genetic and functional basis of isolated 17,20 lyase deficiency. Nature Genet 17 201-205.
94. EL Van Den Akker, JW Koper, AL Boehmer, et al. (2002) Differential inhibition of 17α-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J Clin Endocrinol Metab 87 5714-5721.
95. DH Geller, RJ Auchus and WL Miller (1999) P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b 5. Mol Endocrinol 13 167-175.
96. DP Sherbet, D Tiosano, KM Kwist, et al. (2003) CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J Biol Chem 278 48563-48569.
97. E Hershkovitz, R Parvari, SA Wudy, et al. (2008) Homozygous mutation G539R in the gene for P450 oxidoreductase in a family previously diagnosed as having 17,20-lyase deficiency. J Clin Endocrinol Metab 93 3584-3588.
98. CA Winkel, ML Casey, RJ Worley, et al. (1983) Extraadrenal steroid 21-hydroxylase activity in a woman with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 56 104-107.
99. SH Mellon and WL Miller (1989) Extra-adrenal steroid 21-hydroxylation is not mediated by P450c21. J Clin Invest 84 1497-1502.
100. H Yamazaki and T Shimada (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346 161-169.
101. LG Gomes, N Huang, V Agrawal, et al. (2009) Extraadrenal 21-hydroxylation by CYP2C19 and CYP3A4:Effect on 21-hydroxylase deficiency. J Clin Endocrinol Metab 94 89-95.
102. PC White and PW Speiser (2000) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 21 245-291.
103. J Bristow, MK Tee, SE Gitelman, et al. (1993) Tenascin-X. A novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. J Cell Biol 122 265-278.
104. J Schalkwijk, MC Zweers, PM Steijlen, et al. (2001) A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. N Engl J Med 345 1167-1175.
105. GH Burch, Y Gong, W Liu, et al. (1997) Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. Nature Genet 17 104-108.
106. A Helmburg, M Tusie-Luna, M Tabarelli, et al. (1992) R339H and P453S: CYP21 mutations associated with nonclassic steroid 21-hydroxylase deficiency that are not apparent gene conversion. Mol Endocrinol 6 1318-1322.
107. S Ulick (1976) Diagnosis and nomenclature of the disorders of the terminal portion of aldosterone biosynthetic pathway. J Clin Endocrinol Metab 43 92-96.
108. JD Veldhuis, HE Kulin, RJ Santen, et al. (1980) Inborn error in the terminal step of aldosterone biosynthesis: corticosterone methyl oxidase type II deficiency in a North American pedigree. N Engl J Med 303 118-121.
109. K Yanagibashi, M Haniu, JE Shively, et al. (1986) The synthesis of aldosterone by the adrenal cortex: two zones (fasciculata and glomerulosa) possess one enzyme for 11-, 18-hydroxylation, and aldehyde synthesis. J Biol Chem 261 3556-3562.
110. K Morohashi, H Yoshioka, O Gotoh, et al. (1987) Molecular cloning and nucleotide sequence of DNA of mitochondrial P-450(11) of bovine adrenal cortex. J Biochem 102 559-568.
111. E Mornet, J Dupont, A Vitek, et al. (1989) Characterization of two genes encoding human steroid 11β-hydroxylase (P45011β). J Biol Chem 264 20961-20967.
112. SH Mellon, SR Bair and H Monis (1995) P450c11B3 mRNA, transcribed from a third P450c11 gene, is expressed in a tissue-specific, developmentally and hormonally regulated fashion in the rodent adrenal, and encodes a protein with both 11-hydroxylase and 18-hydroxylase activities. J Biol Chem 270 1643-1649.
113. KM Carnow, M Tusie-Lung, L Pascoe, et al. (1991) The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocrinol 5 1513-1522.
114. T Kawamoto, Y Mitsuuchi, K Toda, et al. (1992) Role of steroid 11β-hydroxylase and 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 89 1458-1462.
115. PC White, J Dupont, MI New, et al. (1991) A mutation in CYP11B1 (Arg 448→His) associated with steroid 11β-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest 87 1664-1667.
116. PC White, KM Curnow and L Pascoe (1994) Disorders of steroid 11β-hydroxylase isozymes. Endocr Rev 15 421-438.
117. L Pascoe, K Curnow, L Slutsker, et al. (1992) Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 89 4996-5000.
118. GK Fu, AA Portale and WL Miller (1997) Complete structure of the human gene for the vitamin D 1α-hydroxyase, P450c1α. DNA Cell Biol 16 1499-1507.
119. CD Clyne, Y Zhang, L Slutsker, et al. (1997) Angiotensin II and potassium regulate human CYP11B2 transcription through common cis-elements. Mol Endocrinol 11 638-649.
120. CE Fardella, DW Hum, H Rodriguez, et al. (1996) Gene conversion in the CYP11B2 gene encoding aldosterone synthase (P450c11AS) is associated with, but does not cause, the syndrome of corticosterone methyl oxidase II deficiency. J Clin Endocrinol Metab 81 321-326.
121. R Lifton, RG Dluhy, M Powers, et al. (1992) A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 335 262-265.
122. L Pascoe, K Curnow, L Slutsker, et al. (1992) Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossover between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 89 8327-8331.
123. WR Litchfield, MI New, C Coolidge, et al. (1997) Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 82 3570-3573.
124. CE Fardella, L Mosso, C Gómez-Sánchez, et al. (2000) Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 1863-1867.
125. B Bottner, K Denner and R Bernhardt (1998) Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. Eur J Biochem 252 458-466.
126. KM Curnow, P Mulatero, N Emeric-Blanchouin, et al. (1997) The amino acid substitutions Ser288Gly and Val320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme [letter]. Nat Struct Biol 4 32-35.
127. ER Simpson, MS Mahendroo, GD Means, et al. (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15 342-355.
128. DD Beusen, HL Carrell and DF Covey (1987) Metabolism of 19-methyl-substituted steroids by human placental aromatase. Biochemistry 26 7833-7841.
129. MS Mahendroo, GD Means, CR Mendelson, et al. (1991) Tissue-specific expression of human P450 arom: the promoter responsible in adipose tissue is different from that utilized in placenta. J Biol Chem 266 11276.
130. ER Simpson, MS Mahendroo, GD Means, et al. (1993) Tissue-specific promoters regulate aromatase cytochrome P450 expression. Clin Chem 39 317.
131. FA Conte, MM Grumbach, Y Ito, et al. (1994) A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J Clin Endocrinol Metab 78 1287-1292.
132. MM Grumbach and RJ Auchus (1999) Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84 4677-4694.
133. CR Fisher, KH Graves, AF Parlow, et al. (1998) Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 95 6965-6970.
134. R Voutilainen and WL Miller (1986) Developmental expression of genes for the steroidogenic enzymes P450scc (20,22 desmolase), P450c17 (17α-hydroxylase/17,20 lyase) and P450c21 (21-hydroxylase) in the human fetus. J Clin Endocrinol Metab 63 1145-1150.
135. WL Miller (1998) Steroid hormone biosynthesis and actions in the materno-feto-placental unit. Clin Perinatol 25 799-817.
136. JC Lo, VM Schwitzgebel, JB Tyrrell, et al. (1999) Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 84 930-936.
137. A Morishima, MM Grumbach, ER Simpson, et al. (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80 3689-3698.
138. I Hanukoglu, BS Suh, S Himmelhoch, et al. (1990) Induction and mitochondrial localization of cytochrome P450scc system enzymes in normal and transformed ovarian granulosa cells. J Cell Biol 111 1373-1381.
139. R Voutilainen, J Picado-Leonard, AM DiBlasio, et al. (1988) Hormonal and developmental regulation of human adrenodoxin mRNA in steroidogenic tissues. J Clin Endocrinol Metab 66 383-388.
140. A Müller, JJ Müller, YA Müller, et al. (1998) New aspects of electron transfer revealed by the crystal structure of a truncated bovine adrenodoxin, Adx(4-108). Structure 6 269-280.
141. VM Coghlan and LE Vickery (1991) Site-specific mutations in human ferredoxin that affect binding to ferredoxin reductase and cytochrome P450scc. J Biol Chem 266 18606-18612.
142. LE Vickery (1997) Molecular recognition and electron transfer in mitochondrial steroid hydroxylase systems. Steroids 62 124-127.
143. A Wada and MR Waterman (1992) Identification by site-directed mutagenesis of two lysine residues in cholesterol side chain cleavage cytochrome P450 that are essential for adrenodoxin binding. J Biol Chem 267 22877-22882.
144. ST Brentano, SM Black, D Lin, et al. (1992) cAMP post-transcriptionally diminishes the abundance of adrenodoxin reductase mRNA. Proc Natl Acad Sci USA 89 4099-4103.
145. D Lin, Y Shi and WL Miller (1990) Cloning and sequence of the human adrenodoxin reductase gene. Proc Natl Acad Sci USA 87 8516-8520.
146. RS Sparkes, I Klisak and WL Miller (1991) Regional mapping of genes encoding human steroidogenic enzymes: P450scc to 15q23-q24, adrenodoxin to 11q22; adrenodoxin reductase to 17q24-q25; and P450c17 to 10q24-q25. DNA Cell Biol 10 359-365.
147. SB Solish, J Picado-Leonard, Y Morel, et al. (1988) Human adrenodoxin reductase: two mRNAs encoded by a single gene of chromosome 17cen→q25 are expressed in steroidogenic tissues. Proc Natl Acad Sci USA 71 7104-7108.
148. ME Brandt and LE Vickery (1992) Expression and characterization of human mitochondrial ferredoxin reductase in Escherichia coli. Arch Biochem Biophys 294 735-740.
149. MR Freeman, A Dobritsa, P Gaines, et al. (1999) The dare gene: steroid hormone production, olfactory behavior, and neural degeneration in Drosophila. Development 126 4591-4602.
150. GA Ziegler, C Vonrhein, I Hanukoglu, et al. (1999) The structure of adrenodoxin reductase of mitochondrial P450 systems: electron transfer for steroid biosynthesis. J Mol Biol 289 981-990.
151. ME Brandt and LE Vickery (1993) Charge pair interactions stabilizing ferredoxin-ferredoxin reductase complexes. Identification by complementary site-specific mutations. J Biol Chem 268 17126-17130.
152. M Wang, DL Roberts, R Paschke, et al. (1997) Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci USA 94 8411-8416.
153. I Sevrioukova, L Huiying, H Zhong, et al. (1999) Structure of a cytochrome P450-redox partner electron-transfer complex. Proceedings of the National Academy of Sciences (USA) 96 1863-1868.
154. CA Hasemann, RG Kurumbail, SS Boddupalli, et al. (1995) Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 2 41-62.
155. RE Peterson, J Imperato-McGinley, T Gautier, et al. (1985) Male pseudohermaphroditism due to multiple defects in steroid-biosynthetic microsomal mixed-function oxidases. A new variant of congenital adrenal hyperplasia. N Engl J Med 313 1182-1191.
156. C Shackleton and E Malunowicz (2003) Apparent pregnene hydroxylation deficiency (APHD): seeking the parentage of an orphan metabolome. Steroids 68 707-717.
157. W Reardon, A Smith, JW Honour, et al. (2000) Evidence for digenic inheritance in some cases of Antley-Bixler syndrome? J Med Genet 37 26-32.
158. CE Flück, T Tajima, AV Pandey, et al. (2004) Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 36 228-230.
159. N Huang, AV Pandey, V Agrawal, et al. (2005) Diversity and function of mutations in P450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 76 729-749.
160. RR Scott and WL Miller (2008) Genetic and clinical features of P450 oxidoreductase deficiency. Horm Res 69 266-275.
161. AL Shen, KA O’Leary and CB Kasper (2002) Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277 6536-6541.
162. DM Otto, CJ Henderson, D Carrie, et al. (2003) Identification of novel roles of the cytochrome P450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 23 6103-6116.
163. CJ Henderson, DM Otto, D Carrie, et al. (2003) Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 278 13480-13486.
164. J Gu, Y Weng, QY Zhang, et al. (2003) Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 278 25895-25901.
165. RR Scott, LG Gomes, N Huang, et al. (2007) Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J Clin Endocrinol Metab 92 2318-2322.
166. N Huang, V Agrawal, KM Giacomini, et al. (2008) Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 105 1733-1738.
167. LG Gomes, N Huang, V Agrawal, et al. (2008) The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab 93 2913-2916.
168. V Agrawal, N Huang and WL Miller (2008) Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 18 569-576.
169. A Bridges, L Gruenke, YT Chang, et al. (1998) Identification of the binding site on cytochrome P450 2B4 for cytochrome b 5 and cytochrome P450 reductase. J Biol Chem 273 17036-17049.
170. H Yamazaki, WW Johnson, YF Ueng, et al. (1996) Lack of electron transfer from cytochrome b 5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b 5. J Biol Chem 271 27438-27444.
171. FW Muskett, GP Kelly and D Whitford (1996) The solution structure of bovine ferricytochrome b 5 determined using heteronuclear NMR methods. J Mol Biol 258 172-189.
172. CJ Falzone, MR Mayer, EL Whiteman, et al. (1996) Design challenges for hemoproteins: the solution structure of apocytochrome b 5. Biochemistry 35 6519-6526.
173. P Lee-Robichaud, MA Kaderbhai, N Kaderbhai, et al. (1997) Interaction of human CYP17 (P-45017α, 17α-hydroxylase-17,20-lyase) with cytochrome b 5: importance of the orientation of the hydrophobic domain of cytochrome b 5. Biochem J 321 857-863.
174. JL Naffin-Olivos and RJ Auchus (2006) Human cytochrome b 5 requires residues E48 and E49 to stimulate the 17, 20-lyase activity of cytochrome P450c17. Biochemistry 46 100-108.
175. JL Thomas, C Frieden, WE Nash, et al. (1995) An NADH-induced conformational change that mediates the sequential 3β-hydroxysteroid dehydrogenase/isomerase activities is supported by affinity labeling and the time-dependent activation of isomerase. J Biol Chem 270 21003-21008.
176. JL Thomas, RP Myers and RC Strickler (1989) Human placental 3β-hydroxy-5-ene-steroid dehydrogenase and steroid 5/4-ene-isomerase: purification from mitochondria and kinetic profiles, biophysical characterization of the purified mitochondrial and microsomal enzymes. J Steroid Biochem 33 209-217.
177. V Luu-The, Y Lechance, C Labrie, et al. (1989) Full length cDNA structure and deduced amino acid sequence of human 3β-hydroxy-5-ene steroid dehydrogenase. Mol Endocrinol 3 1310-1312.
178. E Rhéaume, Y Lachance, HL Zhao, et al. (1991) Structure and expression of a new complementary DNA encoding the almost exclusive 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase in human adrenals and gonads. Mol Endocrinol 5 1147-1157.
179. JL Thomas, EA Berko, A Faustino, et al. (1988) Human placental 3β-hydroxy-5-ene-steroid dehydrogenase and steroid 5/4-ene-isomerase: purification from microsomes, substrate kinetics, and inhibition by product steroids. J Steroid Biochem 31 785-793.
180. N Cherradi, MF Rossier, MB Vallotton, et al. (1997) Submitochondrial distribution of three key steroidogenic proteins (steroidogenic acute regulatory protein and cytochrome P450scc and 3β-hydroxysteroid dehydrogenase isomerase enzymes) upon stimulation by intracellular calcium in adrenal glomerulosa cells. J Biol Chem 272 7899-7907.
181. S Mesiano, CL Coulter and RB Jaffe (1993) Localization of cytochrome P450 cholesterol side-chain cleavage, cytochrome P450 17α-hydroxylase/17,20 lyase, and 3β-hydroxysteroid dehydrogenase-isomerase steroidogenic enzymes in human and rhesus monkey fetal adrenal glands: reappraisal of functional zonation. J Clin Endocrinol Metab 77 1184-1189.
182. A Endoh, SB Kristiansen, PR Casson, et al. (1996) The zona reticularis is the site of biosynthesis of dehydroepiandrosterone and dehydroepiandrosterone sulfate in the adult human adrenal cortex resulting from its low expression of 3β-hydroxysteroid dehydrogenase. J Clin Endocrinol Metab 81 3558-3565.
183. T Remer, KR Boye, MF Hartmann, et al. (2005) Urinary markers of adrenarche: reference values in healthy subjects, aged 3–18 years. J Clin Endocrinol Metab 90 2015-2021.
184. H Peltoketo, V Luu-The, J Simard, et al. (1999) 17β-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J Mol Endocrinol 23 1-11.
185. H Peltoketo, V Isomaa, O Mäenlavsta, et al. (1988) Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett 239 73-77.
186. Y Tremblay, GE Ringler, Y Morel, et al. (1989) Regulation of the gene for estrogenic 17-ketosteroid reductase lying on chromosome 17cen→q25. J Biol Chem 264 20458-20462.
187. V Luu-The, C Labrie, J Simard, et al. (1990) Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes. Mol Endocrinol 4 268-275.
188. V Luu-The, Y Zhang, D Poirier, et al. (1995) Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 55 581-587.
189. RJ Auchus, DF Covey, V Bork, et al. (1988) Solid-state NMR observation of cysteine and lysine Michael adducts of inactivated estradiol dehydrogenase. J Biol Chem 263 11640-11645.
190. D Ghosh, VZ Pletnev, DW Zhu, et al. (1995) Structure of human estrogenic 17β-hydroxysteroid dehydrogenase at 2.20 Å resolution. Structure 3 503-513.
191. H Sasano, AR Frost, R Saitoh, et al. (1996) Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 81 4042-4046.
192. L Wu, M Einstein, WM Geissler, et al. (1993) Expression cloning and characterization of human 17β−hydrosteroid dehydrogenase Type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem 268 12964-12969.
193. ML Casey, PC MacDonald and S Andersson (1994) 17β-Hydroxysteroid dehydrogenase type 2:chromosomal assignment and progestin regulation of gene expression in human endometrium. Journal of Clinical Investigation 94 2135-2141.
194. JM Saez, E De Peretti, AM Morera, et al. (1971) Familial male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect. I. Studies in vivo. J Clin Endocrinol Metab 32 604-610.
195. WM Geissler, DL Davis, L Wu, et al. (1994) Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nature Genet 7 34-39.
196. N Moghrabi, IA Hughes, A Dunaif, et al. (1998) Deleterious missense mutations and silent polymorphism in the human 17β-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab 83 2855-2860.
197. BB Mendonca, IJ Arnhold, W Bloise, et al. (1999) 17β-hydroxysteroid dehydrogenase 3 deficiency in women. J Clin Endocrinol Metab 84 802-804.
198. J Adamski, T Normand, F Leenders, et al. (1995) Molecular cloning of a novel widely expressed human 80 kDa 17β-hydroxysteroid dehydrogenase IV. Biochemical Journal 311 437-443.
199. YM Qin, MH Poutanen, HM Helander, et al. (1997) Peroxisomal multifunctional enzyme of beta-oxidation metabolizing D-3-hydroxyacyl-CoA esters in rat liver: molecular cloning, expression and characterization. Biochem J 321 21-28.
200. EG van Grunsven, E van Berkel, L Ijlst, et al. (1998) Peroxisomal D-hydroxyacyl-CoA dehydrogenase deficiency: resolution of the enzyme defect and its molecular basis in bifunctional protein deficiency. Proc Natl Acad Sci U S A 95 2128-2133.
201. HK Lin, JM Jez, BP Schlegel, et al. (1997) Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution. Molecular Endocrinology 11 1971-1984.
202. Y Deyashiki, A Ogasawara, T Nakayama, et al. (1994) Molecular cloning of two human liver 3α-hydroxysteroid/dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bile-acid binder. Biochem J 299 545-552.
203. M El-Alfy, V Luu-The, XF Huang, et al. (1999) Localization of type 5 17β-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology 140 1481-1491.
204. TM Penning, ME Burczynski, JM Jez, et al. (2000) Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351 67-77.
205. KK Sharma, A Lindqvist, XJ Zhou, et al. (2006) Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues. Mol Cell Endocrinol 248 79-86.
206. MC Byrns, S Steckelbroeck and TM Penning (2008) An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. Biochem Pharmacol 75 484-493.
207. M Goto, K Piper Hanley, J Marcos, et al. (2006) In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 116 953-960.
208. N Bruchovsky and JD Wilson (1968) The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 243 5953-5960.
209. RJ Moore and JD Wilson (1976) Steroid 5α-reductase in cultured human fibroblasts. Biochemical and genetic evidence for two distinct enzyme activities. J Biol Chem 251 5895-5900.
210. EP Jenkins, S Andersson, J Imperato-McGinley, et al. (1992) Genetic and pharmacologic evidence for more than one human steroid 5α−reductase. J Clin Invest 89 293-300.
211. S Andersson, DM Berman, EP Jenkins, et al. (1991) Deletion of a steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354 159-161.
212. AE Thigpen, RI Silver, JM Guileyardo, et al. (1993) Tissue distribution and ontogeny of steroid 5α−reductase isozyme expression. J Clin Invest 92 903-910.
213. DW Frederiksen and JD Wilson (1971) Partial characterization of the nuclear reduced nicotinamide adenine dinucleotide phosphate: Δ4–3-ketosteroid 5α-oxidoreductase of rat prostate. J Biol Chem 246 2584-2593.
214. JD McConnell, R Bruskewitz, P Walsh, et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338 557-563.
215. MS Mahendroo, KM Cala and DW Russell (1996) 5α-reduced androgens play a key role in murine parturition. Mol Endocrinol 10 380-392.
216. MS Mahendroo, JD Wilson, JA Richardson, et al. (2004) Steroid 5α-reductase 1 promotes 5α-androstane-3α,17β-diol synthesis in immature mouse testes by two pathways. Mol Cell Endocrinol 222 113-120.
217. M Khanna, KN Qin, RW Wang, et al. (1995) Substrate specificity, gene structure and tissue-specific distribution of multiple human 3α-hydroxysteroid dehydrogenases. J Biol Chem 270 20162-20168.
218. M Nishizawa, T Nakajima, K Yasuda, et al. (2000) Close kinship of human 20α-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells 5 111-125.
219. R Rupprecht, CA Hauser, T Trapp, et al. (1996) Neurosteroids: molecular mechanisms of action and psychopharmacological significance. J Steroid Biochem Mol Biol 56 163-168.
220. LD Griffin and SH Mellon (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 96 13512-13517.
221. JM Gulbis, S Mann and R MacKinnon (1999) Structure of a voltage-dependent K+ channel beta subunit. Cell 97 943-952.
222. SS Hoog, JE Pawlowski, PM Alzari, et al. (1994) Three-dimensional structure of rat liver 3α- hydroxysteroid/dihydrodiol dehydrogenase: a member of the aldo-keto reductase superfamily. Proc Natl Acad Sci U S A 91 2517-2521.
223. WC Cooper, Y Jin and TM Penning (2007) Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3α-HSD (AKR1C9). J Biol Chem 282 33484-33493.
224. K Ratnam, H Ma and TM Penning (1999) The arginine 276 anchor for NADP(H) dictates fluorescence kinetic transients in 3α-hydroxysteroid dehydrogenase, a representative aldo-keto reductase. Biochemistry 38 7856-7864.
225. JL Napoli (2001) 17β-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17β- and 3α-hydroxysteroid metabolism. Mol Cell Endocrinol 171 103-109.
226. MG Biswas and DW Russell (1997) Expression cloning and characterization of oxidative 17β- and 3α-hydroxysteroid dehydrogenases from rat and human prostate. J Biol Chem 272 15959-15966.
227. SV Chetyrkin, J Hu, WH Gough, et al. (2001) Further characterization of human microsomal 3α-hydroxysteroid dehydrogenase. Arch Biochem Biophys 386 1-10.
228. PC White, T Mune and AK Agarwal (1997) 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18 135-156.
229. GM Tannin, AK Agarwal, C Monder, et al. (1991) The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 266 16653-16658.
230. AK Agarwal, C Monder, B Eckstein, et al. (1989) Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J Biol Chem 264 18939-18943.
231. CCD Moore, SH Mellon, J Murai, et al. (1993) Structure and function of the hepatic form of 11β-hydroxysteroid dehydrogenase in the squirrel monkey, an animal model of glucocorticoid resistance. Endocrinology 133 368-375.
232. AK Agarwal, M-T Tusie-Luna, C Monder, et al. (1990) Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol 4 1827-1832.
233. EA Walker, AM Clark, M Hewison, et al. (2001) Functional expression, characterization, and purification of the catalytic domain of human 11β-hydroxysteroid dehydrogenase type 1. J Biol Chem 276 21343-21350.
234. A Odermatt, P Arnold, A Stauffer, et al. (1999) The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274 28762-28770.
235. A Jamieson, AM Wallace, R Andrew, et al. (1999) Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 84 3570-3574.
236. GG Lavery, EA Walker, A Tiganescu, et al. (2008) Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 93 3827-3832.
237. AL Albiston, VR Obeyesekere, RE Smith, et al. (1994) Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase Type II enzyme. Mol Cell Endocrinol 105 R11-R17.
238. RW Brown, KE Chapman, CRW Edwards, et al. (1993) Human placental 11β-hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD+-dependent isoform. Endocrinology 132 2614-2621.
239. JW Funder, PT Pearce, R Smith, et al. (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242 583-585.
240. T Mune, FM Rogerson, H Nikkila, et al. (1995) Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nature Genet 10 394-399.
241. Z Krozowski, JA MaGuire, AN Stein-Oakley, et al. (1995) Immunohistochemical localization of the 11β-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 80 2203-2209.
242. KX Li, VR Obeyesekere, ZS Krozowski, et al. (1997) Oxoreductase and dehydrogenase activities of the human and rat 11β-hydroxysteroid dehydrogenase type 2 enzyme. Endocrinology 138 2948-2952.
243. P Mulatero, KM Curnow, B Aupetit-Faisant, et al. (1998) Recombinant CYP11B genes encode enzymes that can catalyze conversion of 11-deoxycortisol to cortisol, 18-hydroxycortisol, and 18-oxocortisol. J Clin Endocrinol Metab 83 3996-4001.
244. CE Kater and EG Biglieri (1994) Disorders of steroid 17α-hydroxylase deficiency. Endocrinol Metab Clin North Am 23 341-357.
245. RJ Auchus and WE Rainey (2004) Adrenarche: physiology, biochemistry and human disease. Clin Endocrinol (Oxf) 60 288-296.